sorafenib as maintenance therapy for patients with transplant-ineligible or post-allosct aml
Published 5 months ago • 110 plays • Length 1:33Download video MP4
Download video MP3
Similar videos
-
2:57
sorafenib as soc maintenance after allo-transplant in flt3 aml
-
3:57
the role of post-transplant maintenance therapy in aml
-
6:22
post-transplant maintenance for patients with aml
-
2:23
sorafenib for flt3-itd-positive aml
-
6:35
costem aml highlights: sct & mrd status, sorafenib maintenance & gilteritinib in flt3 aml
-
15:13
my bone marrow transplant journey | day -11 to day 150 | vlog | leukaemia |aml | cancer |
-
14:38
progress report ii - esra zhubi
-
11:06
how could new treatment options improve outcomes in flt3-mutated aml?
-
1:48
do all patients require maintenance therapy following allosct?
-
1:28
the role of allogeneic transplantation in patients with aml in the frontline setting
-
3:27
sorafenib vs placebo in treatment-naïve flt3-itd aml
-
14:43
current research into post-allosct maintenance therapy in aml
-
2:21
post-transplant maintenance strategies in aml
-
3:41
sorafenib maintenace improves outcomes for flt3-itd aml
-
2:49
maintenance therapy in aml: agents under investigation and future outlooks
-
5:00
post-transplant maintenance strategies in aml
-
2:17
the need to improve the quality of life of patients with aml undergoing allosct
-
5:50
is sorafenib the new standard maintenance treatment for flt3 mutant aml?
-
3:15
using targeted therapies to optimize transplant outcomes in aml
-
5:41
phase ii trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia
-
1:19
new treatments for aml